tiragolumab,Carboplatin,Atezolizumab,Etoposide
roche
['lcsm,(-blcsm)', 'tiragolumab', 'sclc']
negative outcome for the addition of tiragalumab to 1st line tx in es-sclc. randomized, db, placebo-controlled study of impower133 +/- tiragolumab (anti-tigit) **unusual baseline demographic with 20% never smokers**
#lcsm #asco22 #sclc 
Fellowship Program Director ????? Hematology & Oncology at George Washington University. Thoracic and Head&Neck cancer.